Anti-LCAT antibody [EPR1383(2)]

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

LCAT also known as lecithin-cholesterol acyltransferase is an enzyme with a molecular mass of approximately 68 kDa. It belongs to the family of esterases and is mainly expressed in the liver. LCAT circulates in the bloodstream playing a significant role in lipid metabolism by catalyzing the formation of cholesteryl esters from free cholesterol and phosphatidylcholine (lecithin) on the surface of high-density lipoproteins (HDL).

Biological function summary

This enzyme functions centrally in the maturation of high-density lipoprotein particles. LCAT interacts with and acts upon HDL converting nascent HDL into mature HDL by catalyzing the esterification of cholesterol. This process results in the sequestration of cholesterol within the core of HDL particles essential for reverse cholesterol transport to the liver. Moreover LCAT does not operate as part of a larger complex but is an active enzyme on its own within various lipid transport processes.

Pathways

LCAT's action significantly influences the lipid metabolism and reverse cholesterol transport pathways. In the lipid metabolism pathway it works closely with apolipoproteins such as apoA-I which serves as an activator. ApoA-I stabilizes the enzymatic action of LCAT promoting cholesterol homeostasis whereas LCAT ensures the efficient transfer of cholesterol to the liver within the reverse cholesterol transport pathway contributing to the maintenance of lipid balance.

Associated diseases and disorders

LCAT deficiency can lead to conditions like familial LCAT deficiency and Fish Eye disease. These disorders are marked by abnormal cholesterol and lipid accumulation due to impaired LCAT activity. Apolipoproteins particularly apoA-I also demonstrate a significant connection as mutations or lack of apoA-I compromise LCAT activation exacerbating hyperlipidemia and related lipid disorders.